Discovery of a Potent and Selective Tyrosine Kinase 2 Inhibitor: TAK-279Silvana Leit, C. E. Masse, William Westlin et al.|Journal of Medicinal Chemistry|2023Cited by 60
Abstract 2894: NTX-452: a non-covalent, potent, selective and highly efficacious WRN inhibitor with best-in-class potential for the treatment of MSI-H tumorsRobert Svensson, Peter J. Tummino, Scott Boiko et al.|Cancer Research|2025Cited by 5
Discovery and characterization of novel inhibitors of CTP synthase 1 (CTPS1) for the treatment of autoimmune and inflammatory diseaseJoshua McElwee, Peter J. Tummino, Neelu Kaila et al.|The Journal of Immunology|2023Cited by 2
Abstract 589: Discovery of NTX-001, a potent Cbl-b inhibitor with antitumor activity in syngeneic modelsFred Csibi-Levin, David Ciccone, Silvana Leit et al.|Cancer Research|2022Cited by 1
Accelerating Lead Optimization away from Anti-Targets: Navigating the Structural Complexity of Promiscuous ADMET ProteinsHowook Hwang, Edward B. Miller, Mee Shelley et al.|ChemRxiv|2026Cited by 0